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One of the more satisfying professional experiences
is helping a patient with a neurological disability
regain strength and function. Chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP) is a
neuropathy syndrome for which there are effective
disease-modifying treatments. It is not surprising,
then, that physicians can be tenacious in the pursuit
of diagnostic testing for CIDP and quick to prescribe
intravenous immunoglobulin (IVIg) and other thera-
pies when it is suspected.
In the absence of a specific biomarker, the diagnosis
of CIDP relies on a combination of clinical features and
ancillary tests, none of which is adequate in isolation. At
least 17 sets of diagnostic criteria have been published,
giving physicians substantial leeway when it comes to
making the diagnosis.1 In an effort to improve consis-
tency, more experts have been advocating for physicians
to use the revised European Federation of Neurological
Societies/Peripheral Nerve Society (EFNS/PNS) diag-
nostic criteria for CIDP.2 These commonly accepted
consensus-derived criteria encompass both typical and
atypical CIDP phenotypes and rely on clinical, electro-
physiologic, laboratory, imaging, and pathologic find-
ings to classify definite, probable, and possible CIDP.
Applying the criteria for possible CIDP, which have a
sensitivity of 91.1% and a specificity of 65.8%, casts the
widest net for patients who may warrant a therapeutic
trial of IVIg or another immunomodulatory agent.3
Chronic inflammatory demyelinating polyradiculo-
neuropathy is overdiagnosed. Forty-seven percent of
patients referred to a tertiary care neuromuscular prac-
tice with the diagnosis of CIDP did not meet EFNS/PNS
criteria for even possible CIDP.4 In another study,5 only
32.2% of 248 patients receiving IVIg for an immune-
mediated neuropathy, including but not limited to CIDP,
were thought to be appropriate for IVIg therapy. Even
this may be an overestimation because the study did not
include insurer-denied cases. In a study of patients
treated by community neurologists for CIDP, only 11%
of those receiving IVIg had documentation sufficient to
meet EFNS/PNS criteria for at least possible CIDP.6
Our propensity to overdiagnose CIDP is not with-
out risk. Physicians may anchor on the wrong diagno-
sis rather than continuing to explore other diagnoses
that would be managed differently. This can lead to
the inappropriate use of expensive and potentially
toxic drugs. In one study, patients in whom CIDP had
been misdiagnosed were treated with IVIg for an aver-
age of 1.5 years.4 Patients also may anchor on the
wrong diagnosis. When a misdiagnosis has been given
yet a patient has subjective benefit from therapy,
efforts to discontinue the inappropriate treatment
may strain the physician–patient relationship or con-
tribute to psychological distress in the patient.
There are clear patterns to the ways in which physi-
cians overdiagnose CIDP. One of the most common
patterns is overreliance on patient-reported percep-
tions of treatment benefit. The placebo effect of IVIg
can be so high that patients with CIDP and those in
whom CIDP has been misdiagnosed report similar ben-
efits from treatment.4 When objective measures of
strength are used, patients with a correct diagnosis of
CIDP are much more likely to improve than those with
an incorrect diagnosis.
Another common factor that leads to the mis-
diagnosis of CIDP is overinterpretation of demyelinat-
ing features based on nerve conduction studies. This
includes misclassification of mild conduction velocity
slowing in motor nerves with a low compound muscle
action potential amplitude or in patients with a condi-
tion known to cause mild conduction slowing, such as
diabetes mellitus. Other common pitfalls include mis-
identifying slowing across a common entrapment site
as a sign of a generalized or multifocal demyelinating
disorder or overcalling conduction block or slowing
that is more likely due to technical factors.7
Putting too much stock in mildly to moderately ele-
vated cerebrospinal fluid (CSF) protein levels can also
lead to the misdiagnosis of CIDP. The EFNS/PNS
criteria for CIDP list “elevated protein” in the CSF as a
supportive criterion but do not define that further.
Although most clinical laboratories use an upper ref-
erence limit (URL) of 45 mg/dl to define elevated
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protein, there is emerging evidence to suggest that
higher, age-matched URL should be implemented
(50 mg/dl for patients of <50 years and 60 mg/dl for
patients ≥50 years).8
In this issue of Muscle & Nerve, Breiner et al.9 applied
different sets of criteria with higher protein URLs to
patient cohorts that were either correctly or incorrectly
diagnosed with CIDP.
Cerebrospinal fluid protein elevation was found in
both CIDP and misdiagnosed CIDP groups, but the
group in which CIDP had been misdiagnosed tended to
havemoremild elevations (median 53mg/dl) compared
with the group in which CIDP had been correctly diag-
nosed (mean 105 mg/dl). Applying the higher URL led
to a decline in false-positive results without changing the
overall detection rate of CIDPwith EFNS/PNS criteria.
To understand why the CIDP detection rate did not
change with the higher URLs, it is important to appre-
ciate the limited role that elevated CSF protein has in
the EFNS/PNS criteria for CIDP. All of the patients in
whom CIDP had been correctly-diagnosed in the
Breiner et al.9 study met clinical and electrodiagnostic
criteria, which are mandatory for all 3 diagnostic
categories—definite, probable, and possible CIDP. Ele-
vated CSF protein is considered a supportive criterion
for CIDP. Other supportive criteria include an objec-
tive response to therapy or specific abnormalities on
MRI, somatosensory evoked potentials, or nerve biopsy.
Supportive criteria, when present, may differentiate
among the 3 CIDP categories but are not used to dis-
tinguish possible CIDP from not CIDP. Thus, if one
is willing to offer immunomodulatory therapy to any
patient with possible CIDP or better, CSF analysis would
have no role in treatment decisions.
If clinical decision-making depended on categoriz-
ing CIDP rather than only identifying the presence or
absence of CIDP, CSF analysis would have a theoretical
value. In the EFNS/PNS criteria, the presence of ele-
vated CSF protein can move a patient from possible to
probable or probable to definite CIDP. In the study by
Breiner et al.,9 43 patients in whom CIDP had been
correctly diagnosed underwent CSF analysis. Within
this cohort, an elevated CSF protein level was the sole
supportive criterion in only 1 case. Therefore, CSF
analysis did not even have the potential to influence
the categorization of CIDP in 97% of cases. This sug-
gests that the role of CSF analysis in CIDP may be low,
even if a physician considers CIDP categorization as a
factor in medical decision making.
Additional study is required to determine whether
the rigid application of EFNS/PNS criteria correlate
with disease activity, treatment response, and out-
come. The international CIDP outcome study (ICOS)
is following treatment outcomes in a cohort of
patients that meet standard EFNS/PNS criteria and in
another cohort of patients that meet clinical and sup-
portive criteria without electrodiagnostic criteria.10 If
the study finds evidence of treatment effect in the lat-
ter group, the value of CSF analysis in the initial diag-
nosis of CIDP may be augmented.
No matter the results of the ICOS study, the asser-
tion that lumbar puncture has limited value in the
workup of CIDP must be balanced with several caveats.
The EFNS/PNS clinical criteria for CIDP rely on the
physician’s evaluations of strength, deep tendon
reflexes, and time course of symptoms. These are sub-
ject to human interpretation, and borderline findings
may lead to diagnostic uncertainty. In these cases,
when rigid application of the EFNS/PNS criteria may
not feasible, elevated CSF protein levels may sway the
physician toward a CIDP diagnosis. Other supportive
criteria may also have value in these cases, but CSF
analysis may be more widely available than spine MRI,
evoked potential studies, and nerve biopsy. Finally,
CSF analysis may include measurements of white blood
cells and other constituents that aid in screening for
infectious or neoplastic processes that can mimic CIDP
or other neuropathy phenotypes.
The Breiner et al.9 study informs the discussion about
the misdiagnosis of CIDP. Cerebrospinal fluid analysis is
probably overused in the routine evaluation of CIDP
and may contribute more to the misdiagnosis than to
the correct diagnosis of CIDP. In the absence of support-
ive clinical and electrodiagnostic data, the specificity of
elevated CSF protein is low, and the primary value of
CSF analysis is to rule out alternative diagnoses. When
patients meet minimal mandatory criteria for CIDP, ele-
vated CSF protein is a supportive criterion that may help
further categorize the diagnosis. In this context, stan-
dardized, age-matched, evidence-based reference values
for CSF protein should be adopted by clinicians and clin-
ical laboratories.
There are other ways to reduce the misdiagnosis of
CIDP. Foremost, we must improve use of and adher-
ence to CIDP diagnostic guidelines, with particular
attention to correct interpretation of electrodiagnostic
data. Neuromuscular physicians should become profi-
cient in applying diagnostic criteria and offer expert
consultation for equivocal cases. When patients are
treated for CIDP, there must be serial clinical evalua-
tions to detect objective indicators of treatment efficacy.
This will allow us to limit the overuse of expensive,
scarce, and potentially harmful resources.
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